Cargando…

Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug TH-302

Previous reports have suggested that the hypoxic microenvironment provides a niche that supports tumor stem cells, and that this might explain clinical observations linking hypoxia to metastasis. To test this, we examined the effects of a hypoxia-activated prodrug, TH-302, on the tumor-initiating ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lohse, Ines, Rasowski, Joanna, Cao, Pinjiang, Pintilie, Melania, Do, Trevor, Tsao, Ming-Sound, Hill, Richard P., Hedley, David W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Priority Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085103/ https://www.ncbi.nlm.nih.gov/pubmed/27248663 http://dx.doi.org/10.18632/oncotarget.9654

Ejemplares similares

Assessment of Hypoxia in the Stroma of Patient-Derived Pancreatic Tumor Xenografts
por: Lohse, Ines, et al.
Publicado: (2014)

Activity of the novel polo-like kinase 4 inhibitor CFI-400945 in pancreatic cancer patient-derived xenografts
por: Lohse, Ines, et al.
Publicado: (2016)

The Hypoxia-Activated Prodrug TH-302: Exploiting Hypoxia in Cancer Therapy
por: Li, Yue, et al.
Publicado: (2021)

MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts
por: Zhang, Xiaomeng, et al.
Publicado: (2016)

Hypoxia-activated prodrug TH-302 decreased survival rate of canine lymphoma cells under hypoxic condition
por: Yamazaki, Hiroki, et al.
Publicado: (2017)

Digital quantitative tissue image analysis of hypoxia in resected pancreatic ductal adenocarcinomas
por: Siddiqui, Iram, et al.
Publicado: (2022)

Pyruvate sensitizes pancreatic tumors to hypoxia-activated prodrug TH-302
por: Wojtkowiak, Jonathan W, et al.
Publicado: (2015)

Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer
por: Sun, Jessica D, et al.
Publicado: (2015)

Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts
por: Brana, Irene, et al.
Publicado: (2017)

Optimizing Drug Response Study Design in Patient-Derived Tumor Xenografts
por: Weiss, Jessica, et al.
Publicado: (2022)

Evaluation of the “Steal” Phenomenon on the Efficacy of Hypoxia Activated Prodrug TH-302 in Pancreatic Cancer
por: Bailey, Kate M., et al.
Publicado: (2014)

Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo
por: Huang, Yan, et al.
Publicado: (2018)

Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts
por: Lohse, Ines, et al.
Publicado: (2016)

Characterization of the Tumor-Microenvironment in Patient-Derived Cervix Xenografts (OCICx)
por: Chaudary, Naz, et al.
Publicado: (2012)

Hedgehog inhibition enhances efficacy of radiation and cisplatin in orthotopic cervical cancer xenografts
por: Chaudary, Naz, et al.
Publicado: (2017)

Resolution of Cullen's sign in patient with metastatic melanoma responding to hypoxia-activated prodrug TH-302
por: Weiss, Glen J., et al.
Publicado: (2011)

Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition
por: Meng, Fanying, et al.
Publicado: (2015)

Hypoxia Imaging With PET Correlates With Antitumor Activity of the Hypoxia-Activated Prodrug Evofosfamide (TH-302) in Rodent Glioma Models
por: Stokes, Ashley M., et al.
Publicado: (2016)

Anticancer efficacy of the hypoxia‐activated prodrug evofosfamide (TH‐302) in osteolytic breast cancer murine models
por: Liapis, Vasilios, et al.
Publicado: (2016)

Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs
por: Phillips, Roger M.
Publicado: (2016)

Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models()
por: Kumar, Sushil, et al.
Publicado: (2018)

Heat acclimation and cross tolerance to hypoxia: Bridging the gap between cellular and systemic responses
por: Ely, Brett R, et al.
Publicado: (2014)

Pyruvate Induces Transient Tumor Hypoxia by Enhancing Mitochondrial Oxygen Consumption and Potentiates the Anti-Tumor Effect of a Hypoxia-Activated Prodrug TH-302
por: Takakusagi, Yoichi, et al.
Publicado: (2014)

An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect()()
por: Hong, Cho Rong, et al.
Publicado: (2018)

Radiofrequency Ablation Remodels the Tumor Microenvironment and Promotes Neutrophil-Mediated Abscopal Immunomodulation in Pancreatic Cancer
por: Faraoni, Erika Y., et al.
Publicado: (2023)

A Combination of Radiation and the Hypoxia-Activated Prodrug Evofosfamide (TH-302) is Efficacious against a Human Orthotopic Pancreatic Tumor Model()()
por: Hajj, Carla, et al.
Publicado: (2017)

BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts
por: Lohse, I, et al.
Publicado: (2015)

Comparison of SARS-CoV-2 RT-PCR on a high-throughput molecular diagnostic platform and the cobas SARS-CoV-2 test for the diagnostic of COVID-19 on various clinical samples
por: Opota, Onya, et al.
Publicado: (2020)

Addition of multiple rare SNPs to known common variants improves the association between disease and gene in the Genetic Analysis Workshop 17 data
por: Sykes, Jenna, et al.
Publicado: (2011)

Targeting DNA topoisomerase IIα (TOP2A) in the hypoxic tumour microenvironment using unidirectional hypoxia‐activated prodrugs (uHAPs)
por: Smith, Paul J., et al.
Publicado: (2022)

TH-302-loaded nanodrug reshapes the hypoxic tumour microenvironment and enhances PD-1 blockade efficacy in gastric cancer
por: Wang, Zhixiong, et al.
Publicado: (2023)

PRDX2 and PRDX4 are negative regulators of hypoxia-inducible factors under conditions of prolonged hypoxia
por: Luo, Weibo, et al.
Publicado: (2016)

A novel peptide that inhibits E2F transcription and regresses prostate tumor xenografts
por: Xie, Xiaoqi, et al.
Publicado: (2014)

Inhibition of porcupine prolongs metastasis free survival in a mouse xenograft model of Ewing sarcoma
por: Hayashi, Masanori, et al.
Publicado: (2017)

Optimized application of penalized regression methods to diverse genomic data
por: Waldron, Levi, et al.
Publicado: (2011)

Pharmacological inhibition of p38 MAPK reduces tumor growth in patient-derived xenografts from colon tumors
por: Gupta, Jalaj, et al.
Publicado: (2015)

Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts
por: Wei, Lei, et al.
Publicado: (2016)

ASXL1 mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts
por: Valletta, Simona, et al.
Publicado: (2015)

Hypoxia-inducible factors enhance glutamate signaling in cancer cells
por: Hu, Hongxia, et al.
Publicado: (2014)

Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment
por: Shay, Gemma, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_h31ukqbru7bu7sbr7j1lgsps85